ABCC5

Summary

ABCC5 (ATP binding cassette subfamily C member 5, HGNC:56) is a protein-coding gene on chromosome 3q27.1, encoding ATP-binding cassette sub-family C member 5 (O15440). ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds, and xenobiotics from cells.

The protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MRP subfamily which is involved in multi-drug resistance. This protein functions in the cellular export of its substrate, cyclic nucleotides. This export contributes to the degradation of phosphodiesterases and possibly an elimination pathway for cyclic nucleotides. Studies show that this protein provides resistance to thiopurine anticancer drugs, 6-mercatopurine and thioguanine, and the anti-HIV drug 9-(2-phosphonylmethoxyethyl)adenine. This protein may be involved in resistance to thiopurines in acute lymphoblastic leukemia and antiretroviral nucleoside analogs in HIV-infected patients. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 10057 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 194 total — 12 pathogenic, 4 likely-pathogenic
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005688

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:56
Approved symbol	ABCC5
Name	ATP binding cassette subfamily C member 5
Location	3q27.1
Locus type	gene with protein product
Status	Approved
Aliases	MRP5, SMRP, EST277145, MOAT-C
Ensembl gene	ENSG00000114770
Ensembl biotype	protein_coding
OMIM	605251
Entrez	10057

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 17 protein_coding, 4 nonsense_mediated_decay, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000265586, ENST00000334444, ENST00000382494, ENST00000392579, ENST00000427120, ENST00000437205, ENST00000437341, ENST00000438979, ENST00000443376, ENST00000443497, ENST00000446941, ENST00000476402, ENST00000492216, ENST00000898238, ENST00000915403, ENST00000956861, ENST00000956862, ENST00000956863, ENST00000956864, ENST00000956865, ENST00000956866, ENST00000956867, ENST00000956868

RefSeq mRNA: 3 — MANE Select: NM_005688 NM_001023587, NM_001320032, NM_005688

CCDS: CCDS33898, CCDS43176

Canonical transcript exons

ENST00000334444 — 30 exons

Exon	Start	End
ENSE00000780809	183987770	183987917
ENSE00000780817	183971563	183971919
ENSE00001079263	183977517	183977624
ENSE00001899220	184017830	184017884
ENSE00001913353	183919934	183921401
ENSE00002701825	184014264	184014447
ENSE00003465075	183963385	183963588
ENSE00003469725	183981727	183981874
ENSE00003487102	183965377	183965501
ENSE00003494842	183978503	183978651
ENSE00003501368	183965185	183965257
ENSE00003520167	183927330	183927443
ENSE00003520675	183928747	183928825
ENSE00003527340	183953086	183953270
ENSE00003545580	183967695	183967766
ENSE00003560602	183982774	183983007
ENSE00003563405	183959733	183959835
ENSE00003569634	183945850	183945939
ENSE00003574200	183937901	183938060
ENSE00003575348	183947324	183947510
ENSE00003585733	183989226	183989383
ENSE00003598069	183951441	183951570
ENSE00003640818	183949972	183950125
ENSE00003648090	183925555	183925719
ENSE00003656920	183949753	183949881
ENSE00003660537	183982451	183982624
ENSE00003663566	183951857	183952003
ENSE00003670552	183942727	183942916
ENSE00003678472	183961511	183961654
ENSE00003691819	183988572	183988727

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 97.41.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.8317 / max 200.9506, expressed in 1758 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45863	12.8317	1758

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	97.41	gold quality
cerebellar hemisphere	UBERON:0002245	97.28	gold quality
cerebellar cortex	UBERON:0002129	97.18	gold quality
gastrocnemius	UBERON:0001388	97.10	gold quality
middle temporal gyrus	UBERON:0002771	97.10	gold quality
pigmented layer of retina	UBERON:0001782	96.82	gold quality
retina	UBERON:0000966	96.79	gold quality
muscle of leg	UBERON:0001383	96.29	gold quality
cerebellum	UBERON:0002037	96.09	gold quality
tibialis anterior	UBERON:0001385	95.97	gold quality
apex of heart	UBERON:0002098	94.96	gold quality
primary visual cortex	UBERON:0002436	94.68	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.63	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.45	gold quality
lower esophagus mucosa	UBERON:0035834	94.32	gold quality
right frontal lobe	UBERON:0002810	93.86	gold quality
body of stomach	UBERON:0001161	93.74	gold quality
right atrium auricular region	UBERON:0006631	93.64	gold quality
muscle organ	UBERON:0001630	93.57	gold quality
skeletal muscle organ	UBERON:0014892	93.57	gold quality
esophagus mucosa	UBERON:0002469	93.30	gold quality
vagina	UBERON:0000996	92.89	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.88	gold quality
deltoid	UBERON:0001476	92.82	gold quality
endometrium epithelium	UBERON:0004811	92.34	gold quality
heart left ventricle	UBERON:0002084	92.32	gold quality
adenohypophysis	UBERON:0002196	92.27	gold quality
stomach	UBERON:0000945	92.26	gold quality
metanephros cortex	UBERON:0010533	92.17	gold quality
pituitary gland	UBERON:0000007	92.16	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	13.44
E-MTAB-7249	yes	11.11
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR

miRNA regulators (miRDB)

146 targeting ABCC5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-548P	99.98	72.25	3784
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-3658	99.96	73.87	4379

Literature-anchored findings (GeneRIF, showing 40)

• MRP4 and MRP5 are low affinity cyclic nucleotide transporters that may at best function as overflow pumps, decreasing steep increases in cGMP levels under conditions where cGMP synthesis is strongly induced and phosphodiesterase activity is limiting (PMID:12637526)
• MRP1 and MRP5 increase with trophoblast maturation, suggesting a particular role for these proteins in the organ functional developmen (PMID:12646196)
• the affinity of MRP4 and MRP5 for nucleotide-based substrates is low. (PMID:12695538)
• Localized in cardiac and cardiovascular myocytes as well as endothelial cells with increased expression in ischemic cardiomyopathy. MRP5-mediated cellular export may represent novel, disease-dependent pathway for cGMP removal from cardiac cells. (PMID:14507663)
• MRP5 expression depends on gestational age and varies throughout the differentiation process. (PMID:15631998)
• Upregulation of MRP5 expression is associated with pancreatic carcinoma (PMID:15688370)
• analysis of linkage disequilibrium at the nucleotide analogue transporter ABCC5 gene locus (PMID:15861033)
• Plant flavonoids were able to reverse drug resistance in human cells transfected with ABCC5 (PMID:16156793)
• We have isolated three novel ABCC5 splice variants and characterized their role in the regulation of ABCC5 gene expression. One ABCC5 splice variant produces a truncated ABCC5 protein isoform with thus far unknown functional properties in the retina. (PMID:17521428)
• cGMP may be a physiological regulator of hyaluronan export at the level of the export MRP5 (PMID:17540771)
• analysis of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5) (PMID:17803828)
• Celecoxib upregulates MRP5 in colon cancer and results in lack of synergy with standard chemotherapy. (PMID:18690847)
• MRP3, MRP4, and MRP5 are upregulated in 5-fluorouracil-resistant cells, and MRP5 contributes to 5-FU resistance in pancreatic carcinoma cells. (PMID:19077464)
• Sodium influx is not directly coupled to MRP4/5-mediated cyclic nucleotide efflux, is independent of the status of transporter activity, and determines the baseline membrane potential, which in turns modulates MRP4/5-mediated cyclic nucleotide efflux. (PMID:19903828)
• Results identify key membrane transporters OATP2B1, MRP1, MRP4, and MRP5 as modulators of skeletal muscle statin exposure and toxicity. (PMID:19940267)
• MDR1, MRP2, MRP3 and MRP5 levels are decreased by tetramethylpyrazine in human hepatocellular carcinoma cells (PMID:19956884)
• Results support the idea that isolating survivin and MRP5+ CTCs may help in the selection of metastatic colorectal cancer patients resistant to standard 5-FU and L-OHP based chemotherapy, for which alternative regimens may be appropriate. (PMID:20597995)
• This gene-wide tagging study revealed no association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy (PMID:21449672)
• Findings show that the gene expression of ATP-dependent efflux transporters MRP1, -3, -4, -5, and p-gp fluctuated during stem cell-derived retinal pigment epithelial cells (hESC-RPE) maturation. (PMID:22272278)
• The present results imply that MRP5 index may hold a prognostic role in patients with glioblastoma multiforme (PMID:22278731)
• PDE5 is highly expressed and increases ( approximately 130%) during growth whereas ABCC5 exhibited low to moderate expression, with a moderate increase ( approximately 40%) during growth (PMID:22843873)
• ABCC5 functions as a mediator of breast cancer skeletal metastasis. ABCC5 expression in breast cancer cells is important for efficient osteoclast-mediated bone resorption. (PMID:23174366)
• Further research is needed to clarify whether MRP5 is indicative of malignant pathological features in meningiomas and whether possible therapeutic implications exist (PMID:23271324)
• This locus was associated with an increase in risk of PACG in a separate case-control study of 4,276 primary angle closure glaucoma cases and 18,801 controls (per-allele OR = 1.13 [95% CI: 1.06-1.22], P = 0.00046). (PMID:24603532)
• cCMP is a substrate for MRP5 (PMID:25017019)
• The blockade of ABC transporter MRP5 could help to improve drug effectiveness, reduce tumour growth and prevent recurrence in glioblastoma multiforme. (PMID:25028266)
• ABCC5 transporter is a novel type 2 diabetes susceptibility gene in European and African American populations. (PMID:25117150)
• The present study investigated the time course and dose dependency of the induction of three efflux proteins, P-gp, MRP1 and MRP5, in response to gemcitabine exposure in Capan-2 pancreatic cancer cell line at transcriptional and translational levels. (PMID:25564970)
• We identified several genes (FasL, MSH2, ABCC5, CASP3, and CYP3A4)that showed association with PFS in patients with osteosarcoma. These pharmacogenetic risk factors might be useful to predict treatment outcome (PMID:25829401)
• To identify substrates of orphan transporter ATP-binding cassette subfamily C member 5 (ABCC5), identified a class of metabolites, N-lactoyl-amino acids, and found that a protease, cytosolic nonspecific dipeptidase 2 (CNDP2), catalyzes their formation. (PMID:25964343)
• Survivors of childhood acute lymphoblastic leukemia treated with doxorubicin with the ABCC5 TT-1629 genotype had an average of 8-12% reduction of ventricular ejection and shortening fractions. (PMID:26345518)
• genetic association study in population in Mexico: Data suggest SNPs in ABCC5 (3933+313T>C) are not associated with adverse reactions to methotrexate; they protect against myelosuppression in pediatric patients with ALL (acute lymphoblastic leukemia). (PMID:26353179)
• ABCC5 is a general glutamate conjugate and analog transporter that affects the disposition of endogenous metabolites, toxins, and drugs. (PMID:26515061)
• our work indicated that decreased SLC34A2 expression sensitized BCSCs to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling and shed new light on understanding the mechanism of chemoresistance in BCSCs. This study not only bridges the missing link between stem cell-related transcription factor (Bmi1) and ABC transporter (ABCC5) but also contributes to development of potential therapeutics against breast cancer. (PMID:26546432)
• Deletions of ABCC5 predict good tumor response to neoadjuvant chemotherapy in breast cancer. (PMID:26799285)
• ABCC5 polymorphisms may explain partially the interpatient variability in doxorubicin disposition. (PMID:26975227)
• This study is the first to identify the roles of FOXM1 in drug efflux and paclitaxel resistance by regulating the gene transcription of abcc5, one of the ABC transporters. Small molecular inhibitors of FOXM1 or ABCC5 have the potential to overcome paclitaxel chemoresistance in nasopharyngeal carcinoma (NPC)patients. (PMID:28277541)
• These findings enrich the allelic spectrum of ABCC5 in PACG. We identified no tagging SNP responsible for the association of the whole region. (PMID:28813580)
• MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. (PMID:32828758)
• Association of Single-Nucleotide Polymorphisms in ABCC5 Gene with Primary Angle Closure Glaucoma and the Ocular Biometric Parameters in a Northern Chinese Population. (PMID:32906129)

Cross-species orthologs

14 orthologs

Organism	Symbol	Gene ID
danio_rerio	abcc5	ENSDARG00000061233
mus_musculus	Abcc5	ENSMUSG00000022822
rattus_norvegicus	Abcc5	ENSRNOG00000029178
drosophila_melanogaster	l(2)03659	FBGN0010549
drosophila_melanogaster	CG7627	FBGN0032026
drosophila_melanogaster	MRP	FBGN0032456
drosophila_melanogaster	CG9270	FBGN0032908
drosophila_melanogaster	CG10505	FBGN0034612
drosophila_melanogaster	Mrp5	FBGN0038740
drosophila_melanogaster	rdog	FBGN0039644
drosophila_melanogaster	CG11898	FBGN0039645
drosophila_melanogaster	CG31792	FBGN0051792
drosophila_melanogaster	Mrp4	FBGN0263316
caenorhabditis_elegans		WBGENE00000477

Paralogs (11): CFTR (ENSG00000001626), ABCC8 (ENSG00000006071), ABCC2 (ENSG00000023839), ABCC9 (ENSG00000069431), ABCC6 (ENSG00000091262), ABCC1 (ENSG00000103222), ABCC3 (ENSG00000108846), ABCC11 (ENSG00000121270), ABCC10 (ENSG00000124574), ABCC4 (ENSG00000125257), ABCC12 (ENSG00000140798)

Protein

Protein identifiers

ATP-binding cassette sub-family C member 5 — O15440 (reviewed: O15440)

Alternative names: Multi-specific organic anion transporter C, Multidrug resistance-associated protein 5, SMRP, pABC11

All UniProt accessions (7): A5PKY6, C9JZL5, E9PET4, F8WCY8, F8WDH3, H7C271, O15440

UniProt curated annotations — full annotation on UniProt →

Function. ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds, and xenobiotics from cells. Mediates ATP-dependent transport of endogenous metabolites such as cAMP and cGMP, folic acid and N-lactoyl-amino acids (in vitro). Also acts as a general glutamate conjugate and analog transporter that can limit the brain levels of endogenous metabolites, drugs, and toxins. Confers resistance to the antiviral agent PMEA. Able to transport several anticancer drugs including methotrexate, and nucleotide analogs in vitro, however it does with low affinity, thus the exact role of ABCC5 in mediating resistance still needs to be elucidated. Acts as a heme transporter required for the translocation of cytosolic heme to the secretory pathway. May play a role in energy metabolism by regulating the glucagon-like peptide 1 (GLP-1) secretion from enteroendocrine cells.

Subcellular location. Basolateral cell membrane. Golgi apparatus lumen. Endosome membrane. Cytoplasmic granule. Apical cell membrane.

Tissue specificity. Predominant isoform in retinal pigment epithelium, bladder, and stomach. Ubiquitously expressed, but levels in brain and muscle are especially high. All isoforms are equally expressed in retina.

Activity regulation. cGMP transport is highly sensitive to inhibitors of cGMP phosphodiesterase, such as zaprinast, trequinsin and sildenafil.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. Although other labs have confirmed the ability of ABCC5 to transport cGMP in an ATP-dependent manner, they obtained a much lower affinity for this substrate. The authors conclude that ABCC5 is a low-affinity cyclic nucleotide transporter a major function in cGMP excretion is unlikely.

Similarity. Belongs to the ABC transporter superfamily. ABCC family. Conjugate transporter (TC 3.A.1.208) subfamily.

Isoforms (5)

UniProt ID	Names	Canonical?
O15440-1	1	yes
O15440-2	2, SV1
O15440-3	3, SV2
O15440-4	4, SV3
O15440-5	5

RefSeq proteins (3): NP_001018881, NP_001306961, NP_005679* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003439	ABC_transporter-like_ATP-bd	Domain
IPR003593	AAA+_ATPase	Domain
IPR011527	ABC1_TM_dom	Domain
IPR017871	ABC_transporter-like_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR036640	ABC1_TM_sf	Homologous_superfamily
IPR050173	ABC_transporter_C-like	Family

Pfam: PF00005, PF00664

Enzyme classification (BRENDA):

• EC 7.6.2.3 — ABC-type glutathione-S-conjugate transporter (BRENDA: 8 organisms, 145 substrates, 63 inhibitors, 16 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

7 substrates with measured Km, best-characterized 7. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0865–0.91	5
MONOMETHYLARSONOUS ACID DIGLUTATHIONE[SIDE 1]	0.023–0.033	4
S-(2,4-DINITROPHENYL)GLUTATHIONE[SIDE 1]	0.0141–0.032	2
S-(LEUKOTRIENE C4)GLUTATHIONE[SIDE 1]	0.0001	2
4-(GLUTATHIONE-S-YL)-QUINOLINE-1-OXIDE[SIDE 1]	0.0095	1
ARSENIC TRIGLUTATHIONE[SIDE 1]	0.0003	1
S-GLUTATHIONE[SIDE 1]	12	1

Catalyzed reactions (Rhea), 12 shown:

• 3’,5’-cyclic AMP(in) + ATP + H2O = 3’,5’-cyclic AMP(out) + ADP + phosphate + H(+) (RHEA:66184)
• 3’,5’-cyclic GMP(in) + ATP + H2O = 3’,5’-cyclic GMP(out) + ADP + phosphate + H(+) (RHEA:66188)
• N-[(S)-lactoyl]-L-phenylalanine(in) + ATP + H2O = N-[(S)-lactoyl]-L-phenylalanine(out) + ADP + phosphate + H(+) (RHEA:66720)
• N-acetyl-L-aspartyl-L-glutamate(in) + ATP + H2O = N-acetyl-L-aspartyl-L-glutamate(out) + ADP + phosphate + H(+) (RHEA:66728)
• N-acetyl-L-aspartyl-L-glutamyl-L-glutamate(in) + ATP + H2O = N-acetyl-L-aspartyl-L-glutamyl-L-glutamate(out) + ADP + phosphate + H(+) (RHEA:66732)
• beta-citrylglutamate(in) + ATP + H2O = beta-citrylglutamate(out) + ADP + phosphate + H(+) (RHEA:66736)
• N-acetyl-L-glutamate(in) + ATP + H2O = N-acetyl-L-glutamate(out) + ADP + phosphate + H(+) (RHEA:66740)
• N-acetyl-L-aspartate(in) + ATP + H2O = N-acetyl-L-aspartate(out) + ADP + phosphate + H(+) (RHEA:66744)
• (2S)-2-[5-amino-1-(beta-D-ribosyl)imidazole-4-carboxamido]succinate(in) + ATP + H2O = (2S)-2-[5-amino-1-(beta-D-ribosyl)imidazole-4-carboxamido]succinate(out) + ADP + phosphate + H(+) (RHEA:66752)
• domoate(in) + ATP + H2O = domoate(out) + ADP + phosphate + H(+) (RHEA:66756)
• kainate(in) + ATP + H2O = kainate(out) + ADP + phosphate + H(+) (RHEA:66760)
• folate(in) + ATP + H2O = folate(out) + ADP + phosphate + H(+) (RHEA:66764)

UniProt features (164 total): helix 57, strand 38, turn 17, transmembrane region 13, glycosylation site 8, splice variant 7, modified residue 6, domain 4, compositionally biased region 4, sequence conflict 4, region of interest 3, binding site 2, chain 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
8WI0	ELECTRON MICROSCOPY	2.93
8WI4	ELECTRON MICROSCOPY	3.2
8WI3	ELECTRON MICROSCOPY	3.38
8WI5	ELECTRON MICROSCOPY	3.46
8KCI	ELECTRON MICROSCOPY	3.94
8WI2	ELECTRON MICROSCOPY	4.06

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15440-F1	78.13	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 595–602; 1227–1234

Post-translational modifications (6): 14, 19, 60, 505, 509, 513

Glycosylation sites (8): 494, 636, 684, 890, 897, 1044, 1329, 1417

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-2142845	Hyaluronan metabolism
R-HSA-382556	ABC-family protein mediated transport
R-HSA-9748787	Azathioprine ADME
R-HSA-9753281	Paracetamol ADME
R-HSA-1430728	Metabolism
R-HSA-1630316	Glycosaminoglycan metabolism
R-HSA-2142850
R-HSA-382551	Transport of small molecules
R-HSA-71387	Metabolism of carbohydrates and carbohydrate derivatives
R-HSA-9748784	Drug ADME

MSigDB gene sets: 414 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_UP, SHEPARD_BMYB_MORPHOLINO_UP, GOBP_CIRCULATORY_SYSTEM_PROCESS, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_IRON_COORDINATION_ENTITY_TRANSPORT, BROWNE_HCMV_INFECTION_8HR_UP, GOBP_TRANSITION_METAL_ION_TRANSPORT, GOBP_MODIFIED_AMINO_ACID_TRANSPORT, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, MODULE_493, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, TGACCTY_ERR1_Q2, FOXO4_01, GOBP_XENOBIOTIC_TRANSMEMBRANE_TRANSPORT, GOBP_IRON_ION_TRANSPORT

GO Biological Process (16): xenobiotic metabolic process (GO:0006805), xenobiotic transmembrane transport (GO:0006855), purine nucleotide transport (GO:0015865), hyaluronan biosynthetic process (GO:0030213), glutathione transmembrane transport (GO:0034775), heme transmembrane transport (GO:0035351), xenobiotic transport (GO:0042908), transmembrane transport (GO:0055085), cAMP transport (GO:0070730), cGMP transport (GO:0070731), folate transmembrane transport (GO:0098838), export across plasma membrane (GO:0140115), transport across blood-brain barrier (GO:0150104), carbohydrate derivative transport (GO:1901264), xenobiotic detoxification by transmembrane export across the plasma membrane (GO:1990961), monoatomic anion transmembrane transport (GO:0098656)

GO Molecular Function (15): ATP binding (GO:0005524), obsolete organic anion transmembrane transporter activity (GO:0008514), ABC-type xenobiotic transporter activity (GO:0008559), purine nucleotide transmembrane transporter activity (GO:0015216), heme transmembrane transporter activity (GO:0015232), efflux transmembrane transporter activity (GO:0015562), ATP hydrolysis activity (GO:0016887), macromolecule transmembrane transporter activity (GO:0022884), glutathione transmembrane transporter activity (GO:0034634), ATPase-coupled transmembrane transporter activity (GO:0042626), xenobiotic transmembrane transporter activity (GO:0042910), obsolete ATPase-coupled inorganic anion transmembrane transporter activity (GO:0043225), ABC-type transporter activity (GO:0140359), carbohydrate derivative transmembrane transporter activity (GO:1901505), nucleotide binding (GO:0000166)

GO Cellular Component (8): Golgi lumen (GO:0005796), plasma membrane (GO:0005886), endosome membrane (GO:0010008), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), apical plasma membrane (GO:0016324), endosome (GO:0005768), Golgi apparatus (GO:0005794)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Drug ADME	2
Glycosaminoglycan metabolism	1
Transport of small molecules	1
Metabolism of carbohydrates and carbohydrate derivatives	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transmembrane transporter activity	5
transport	3
xenobiotic transport	2
transmembrane transport	2
heme transport	2
purine ribonucleotide transport	2
cyclic nucleotide transport	2
ATP-dependent activity	2
plasma membrane region	2
endomembrane system	2
metabolic process	1
cellular response to xenobiotic stimulus	1
nucleotide transport	1
glycosaminoglycan biosynthetic process	1
hyaluronan metabolic process	1
glutathione transport	1
tripeptide transmembrane transport	1
iron ion transmembrane transport	1
cellular process	1
adenine nucleotide transport	1
guanine nucleotide transport	1
folic acid transport	1
vitamin transmembrane transport	1
carboxylic acid transmembrane transport	1
export from cell	1
vascular transport	1
xenobiotic export from cell	1
detoxification	1
export across plasma membrane	1
monoatomic anion transport	1
monoatomic ion transmembrane transport	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
xenobiotic transmembrane transporter activity	1
ABC-type transporter activity	1
nucleotide transmembrane transporter activity	1
purine nucleotide transport	1
ribonucleoside triphosphate phosphatase activity	1
glutathione transmembrane transport	1
tripeptide transmembrane transporter activity	1

Protein interactions and networks

STRING

1766 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ABCC5	MRPS7	Q9Y2R9	944
ABCC5	ABCG2	Q9UNQ0	619
ABCC5	ABCF3	Q9NUQ8	597
ABCC5	SLCO2B1	O94956	586
ABCC5	SLC2A1	P11166	585
ABCC5	ABCF2	Q9UG63	565
ABCC5	SLC29A1	Q99808	553
ABCC5	SLCO1A2	P46721	552
ABCC5	ABCE1	P61221	546
ABCC5	ABCG4	Q9H172	530
ABCC5	SLC28A1	O00337	528
ABCC5	SLC28A3	Q9HAS3	526
ABCC5	SLC22A7	Q9Y694	524
ABCC5	ABCC3	O15438	520
ABCC5	ABCG1	P45844	519

IntAct

31 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
ESR1	TRIM24	psi-mi:“MI:0914”(association)	0.640
SCN3B	ABCC5	psi-mi:“MI:0914”(association)	0.530
CLGN	NPC1	psi-mi:“MI:0914”(association)	0.530
SLC30A2	RER1	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
ABCC5	H1-5	psi-mi:“MI:0915”(physical association)	0.400
ABCC5	H1-1	psi-mi:“MI:0915”(physical association)	0.400
SMC2	ABCC5	psi-mi:“MI:0915”(physical association)	0.370
AK2	ABCC5	psi-mi:“MI:0915”(physical association)	0.370
RBP5	ABCC5	psi-mi:“MI:0915”(physical association)	0.370
SERPINA3	ABCC5	psi-mi:“MI:0915”(physical association)	0.370
NUP58	ABCC5	psi-mi:“MI:0914”(association)	0.350
Sesn2	CASTOR2	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
TTMP	TMEM223	psi-mi:“MI:0914”(association)	0.350
RXFP1	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
LGALS9	LGALS8	psi-mi:“MI:0914”(association)	0.350
SAAL1	TMEM223	psi-mi:“MI:0914”(association)	0.350
SLC16A13	ABCC5	psi-mi:“MI:0914”(association)	0.350
SLC27A6	NBAS	psi-mi:“MI:0914”(association)	0.350
TMEM17	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
KRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
KCNK3	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
TIAM1	ABCC5	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (69): ABCC5 (Affinity Capture-RNA), ABCC5 (Affinity Capture-RNA), ABCC5 (Affinity Capture-RNA), ABCC5 (Proximity Label-MS), ABCC5 (Affinity Capture-MS), ABCC5 (Affinity Capture-MS), ABCC5 (Affinity Capture-MS), ABCC5 (Affinity Capture-MS), ABCC5 (Proximity Label-MS), ABCC5 (Proximity Label-MS), ABCC5 (Proximity Label-MS), HIST1H1B (Proximity Label-MS), HIST1H1A (Proximity Label-MS), ABCC5 (Proximity Label-MS), ABCC5 (Proximity Label-MS)

ESM2 similar proteins: A0A059JK44, A0A0D1BUH6, A0A0S6XH62, A0A0U1LQE1, A0A142I732, A0A179H0T5, A0A348AXX9, A0A3G9H9H1, A0A8J9WHR9, A7A063, C8ZCR2, F2Q5G0, F2RPA4, F9X9V4, G4N2B5, I1R9B3, I1RF50, I1S2J9, K0E4D9, K3VYH8, O15440, O60706, P0CE68, P0CE70, P0CU83, P14772, P21441, P38735, P70170, P82451, P9WEL8, Q08D64, Q10185, Q2UPC0, Q4WA92, Q4WSI1, Q4WT65, Q5A762, Q5AV01, Q63563

Diamond homologs: A0A0D1CZ63, A0A0U1LQE1, A0A1U8QTJ9, A2XCD4, A7KVC2, B2RX12, E9Q236, F1M3J4, F9X9V4, G4N2B5, J9VQH1, O15438, O15439, O15440, O31708, O35379, O60706, O70127, O88269, O88563, O95255, P0CE69, P14772, P16875, P16877, P21439, P21440, P32386, P33527, P38735, P39109, P53049, P70170, P82451, P91660, P9WEL8, Q07QX6, Q08201, Q09427, Q0VQP5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

194 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	12
Likely pathogenic	4
Uncertain significance	136
Likely benign	5
Benign	4

Top pathogenic / likely-pathogenic (16)

Variant ID	HGVS	Classification
149685	GRCh38/hg38 3q26.32-29(chr3:176168525-198118383)x3	Pathogenic
152257	GRCh38/hg38 3q25.31-29(chr3:156321878-198113452)x3	Pathogenic
1527063	GRCh37/hg19 3q27.1-27.3(chr3:183178932-186838042)	Pathogenic
153734	GRCh38/hg38 3q26.33-28(chr3:181138664-192512023)x1	Pathogenic
1703654	GRCh37/hg19 3q27.1-28(chr3:183556940-188083060)	Pathogenic
1710512	GRCh37/hg19 3q26.33-27.2(chr3:181062175-185474509)x1	Pathogenic
3062712	GRCh37/hg19 3q26.33-27.2(chr3:179391972-185539073)x1	Pathogenic
3148910	GRCh37/hg19 3q26.33-29(chr3:179313373-197851444)x3	Pathogenic
562847	GRCh37/hg19 3q26.33-29(chr3:182539234-197851986)x3	Pathogenic
562848	GRCh37/hg19 3q26.33-28(chr3:182650681-191275809)x1	Pathogenic
57984	GRCh38/hg38 3q25.31-29(chr3:157293378-198134727)x3	Pathogenic
814497	GRCh37/hg19 3q26.2-28(chr3:169617690-190593854)x3	Pathogenic
151178	GRCh38/hg38 3q27.1-27.2(chr3:184010704-186288926)x1	Likely pathogenic
153971	GRCh38/hg38 3q26.33-27.3(chr3:182319764-186443121)x1	Likely pathogenic
155230	GRCh38/hg38 3q27.1(chr3:183521497-184472038)x1	Likely pathogenic
1707630	GRCh37/hg19 3q26.31-29(chr3:171558472-197871052)x3	Likely pathogenic

SpliceAI

4955 predictions. Top by Δscore:

Variant	Effect	Δscore
3:183921398:CCAC:C	acceptor_gain	1.0000
3:183921399:CAC:C	acceptor_gain	1.0000
3:183921399:CACC:C	acceptor_gain	1.0000
3:183921400:ACCT:A	acceptor_loss	1.0000
3:183921402:C:CC	acceptor_gain	1.0000
3:183921403:T:A	acceptor_loss	1.0000
3:183925715:AGAAT:A	acceptor_gain	1.0000
3:183925716:GAAT:G	acceptor_gain	1.0000
3:183925717:AAT:A	acceptor_gain	1.0000
3:183925718:AT:A	acceptor_gain	1.0000
3:183925718:ATCTG:A	acceptor_gain	1.0000
3:183925719:TCTGC:T	acceptor_gain	1.0000
3:183925720:C:A	acceptor_gain	1.0000
3:183925720:C:CC	acceptor_gain	1.0000
3:183925721:T:G	acceptor_gain	1.0000
3:183925724:C:CT	acceptor_gain	1.0000
3:183925732:C:CT	acceptor_gain	1.0000
3:183925733:A:T	acceptor_gain	1.0000
3:183927324:CCTTA:C	donor_loss	1.0000
3:183927325:CTTA:C	donor_loss	1.0000
3:183927327:TA:T	donor_loss	1.0000
3:183927328:A:AG	donor_loss	1.0000
3:183927440:CAAT:C	acceptor_gain	1.0000
3:183927442:AT:A	acceptor_gain	1.0000
3:183927444:C:CC	acceptor_gain	1.0000
3:183927444:C:T	acceptor_loss	1.0000
3:183927445:T:G	acceptor_loss	1.0000
3:183928745:A:AC	donor_gain	1.0000
3:183928746:C:CC	donor_gain	1.0000
3:183928746:CA:C	donor_gain	1.0000

AlphaMissense

9412 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:183925595:A:T	V1391D	0.999
3:183925607:C:G	R1387P	0.999
3:183925611:G:C	H1386D	0.999
3:183925702:T:A	E1355D	0.999
3:183925702:T:G	E1355D	0.999
3:183925703:T:A	E1355V	0.999
3:183925703:T:C	E1355G	0.999
3:183925703:T:G	E1355A	0.999
3:183927367:A:G	L1337P	0.999
3:183927373:C:G	R1335P	0.999
3:183928772:A:G	L1303P	0.999
3:183937904:A:T	V1284D	0.999
3:183937958:A:G	L1266P	0.999
3:183938057:T:A	K1233M	0.999
3:183938060:C:T	G1232E	0.999
3:183942727:C:A	G1232W	0.999
3:183942732:C:T	G1230E	0.999
3:183942741:C:T	G1227E	0.999
3:183942742:C:A	G1227W	0.999
3:183942742:C:G	G1227R	0.999
3:183942742:C:T	G1227R	0.999
3:183942862:A:G	W1187R	0.999
3:183942862:A:T	W1187R	0.999
3:183945887:C:G	R1156P	0.999
3:183945891:C:G	A1155P	0.999
3:183945908:A:G	L1149P	0.999
3:183947420:G:C	S1106R	0.999
3:183947420:G:T	S1106R	0.999
3:183947422:T:G	S1106R	0.999
3:183947449:A:G	W1097R	0.999

dbSNP variants (sampled 300 via entrez): RS1000004346 (3:183986259 C>A), RS1000034633 (3:183939591 A>G), RS1000064311 (3:183945707 C>A,T), RS1000087614 (3:183942066 G>A,C), RS1000089993 (3:183989659 T>C), RS1000104526 (3:184018155 T>TC), RS1000153935 (3:183922448 G>A,C), RS1000167561 (3:183922491 C>A,T), RS1000184347 (3:183969143 C>T), RS1000189885 (3:184013060 T>C), RS1000223810 (3:183926450 G>A,C,T), RS1000268888 (3:183922109 T>C), RS1000305873 (3:184012622 A>T), RS1000335098 (3:183952475 G>A,T), RS1000349561 (3:183929126 G>A)

Disease associations

OMIM: gene MIM:605251 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (1): Non-syndromic anorectal malformation (Orphanet:557)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST002383_1	Anterior chamber depth	8.000000e-09
GCST004603_257	Platelet count	4.000000e-12
GCST009379_142	Type 2 diabetes	2.000000e-08
GCST90002380_143	Basophil percentage of white cells	4.000000e-09
GCST90002381_196	Eosinophil count	1.000000e-14
GCST90002391_7	Mean corpuscular hemoglobin concentration	1.000000e-09
GCST90002394_264	Monocyte percentage of white cells	1.000000e-17
GCST90002398_436	Neutrophil count	2.000000e-16
GCST90002400_410	Plateletcrit	4.000000e-18
GCST90002401_136	Platelet distribution width	2.000000e-21
GCST90002402_661	Platelet count	4.000000e-34
GCST90002404_70	Red cell distribution width	1.000000e-11
GCST90002407_418	White blood cell count	9.000000e-19

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0007992	basophil percentage of leukocytes
EFO:0004842	eosinophil count
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0007989	monocyte percentage of leukocytes
EFO:0004833	neutrophil count
EFO:0007985	platelet crit
EFO:0007984	platelet component distribution width
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2046258 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 93,593 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL192	SILDENAFIL	4	41,819
CHEMBL932	DIPYRIDAMOLE	4	51,743
CHEMBL285913	TREQUINSIN	2	31

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10937158	Toxicity	3	fluorouracil;irinotecan;leucovorin	Colorectal Neoplasms
rs3749438	Toxicity	3	fluorouracil;irinotecan;leucovorin	Colorectal Neoplasms

PharmGKB variants

21 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs562	ABCC5		0.00	0
rs939338	ABCC5		0.00	0
rs1000002	ABCC5		0.00	0
rs1533682	ABCC5		0.00	0
rs2139560	ABCC5		0.00	0
rs2292997	ABCC5	3	2.50	1	fluorouracil;irinotecan;leucovorin
rs2293001	ABCC5		0.00	0
rs3749438	ABCC5	3	3.25	1	fluorouracil;irinotecan;leucovorin
rs3792581	ABCC5		0.00	0
rs3805111	ABCC5		0.00	0
rs4148557	ABCC5		0.00	0
rs4148572	ABCC5		0.00	0
rs8180093	ABCC5		0.00	0
rs10937158	ABCC5	3	3.25	1	fluorouracil;irinotecan;leucovorin
rs3749442	ABCC5		0.00	0
rs9838667	ABCC5		0.00	0
rs1132776	ABCC5		0.00	0
rs4148575	ABCC5		0.00	0
rs4148579	ABCC5		0.00	0
rs4148580	ABCC5		0.00	0
rs7627754	ABCC5		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — ABCC subfamily

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
compound 2 [PMID: 22380603]	Inhibition	7.19	pKi
sildenafil	Inhibition	5.92	pKi

ChEMBL bioactivities

3 potent at pChembl≥5 of 7 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.18	Ki	65.3	nM	CHEMBL1338248
7.12	Ki	75.3	nM	CHEMBL2047880
5.92	Ki	1200	nM	SILDENAFIL

PubChem BioAssay actives

3 with measured affinity, of 51 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,5-d]pyrimidin-5-yl)phenyl]sulfonylamino]-2-hydroxybenzoic acid	668995: Inhibition of ABCC5 in human erythrocytes assessed as inhibition of ATP-mediated [3H]cGMP uptake in inside-out vesicles after 60 mins by liquid scintillation counting	ki	0.0653	uM
5-[[3-(3-tert-butyl-1-methyl-7-oxo-6H-pyrazolo[4,5-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonylamino]-2-hydroxybenzoic acid	668995: Inhibition of ABCC5 in human erythrocytes assessed as inhibition of ATP-mediated [3H]cGMP uptake in inside-out vesicles after 60 mins by liquid scintillation counting	ki	0.0753	uM
Sildenafil	668995: Inhibition of ABCC5 in human erythrocytes assessed as inhibition of ATP-mediated [3H]cGMP uptake in inside-out vesicles after 60 mins by liquid scintillation counting	ki	1.2000	uM

CTD chemical–gene interactions

101 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cisplatin	decreases response to substance, affects cotreatment, increases expression	4
Estradiol	affects cotreatment, decreases expression, increases expression	4
bisphenol A	increases expression, decreases expression	3
Zidovudine	increases expression, increases export	3
afimoxifene	decreases expression, decreases reaction, increases expression	2
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
perfluorooctanoic acid	decreases expression	2
potassium chromate(VI)	affects cotreatment, decreases expression, increases expression	2
chrysin	affects reaction, increases transport, decreases expression	2
5(6)-carboxy-2’,7’-dichlorofluorescein	increases transport, increases uptake, decreases reaction	2
Oxaliplatin	affects response to substance, decreases response to substance	2
Acetaminophen	increases expression, affects expression	2
Benzo(a)pyrene	decreases methylation, increases expression	2
Fluorouracil	decreases reaction, decreases response to substance, increases export	2
Glutathione	affects reaction, increases transport, affects transport	2
Methotrexate	decreases response to substance, decreases expression	2
Thioguanine	decreases reaction, decreases response to substance	2
Valproic Acid	affects expression, increases expression	2
Particulate Matter	increases expression, decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
4’-methoxy-1-naphthylfenoterol	decreases expression	1
FR900359	decreases phosphorylation	1
ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate	decreases expression	1
dicrotophos	increases expression	1
5-fluorouridine	increases export	1
daidzein	decreases reaction, decreases response to substance, increases export	1
naringenin	increases export, decreases reaction, decreases response to substance	1
2’-deoxyuridylic acid	increases export	1
2-butenal	decreases expression	1
hesperetin	decreases reaction, decreases response to substance, increases export	1

ChEMBL screening assays

24 unique, capped per target: 17 functional, 4 admet, 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2049558	Binding	Inhibition of ABCC5 in human erythrocytes assessed as inhibition of ATP-mediated [3H]cGMP uptake in inside-out vesicles at 32 uM after 60 mins by liquid scintillation counting	Novel cGMP efflux inhibitors identified by virtual ligand screening (VLS) and confirmed by experimental studies. — J Med Chem
CHEMBL2075979	Functional	TP_TRANSPORTER: uptake in membrane vesicles from MRP5-expressing V79 cells	The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. — J Biol Chem
CHEMBL3532855	ADMET	Activity at MRP5 in human Colo-357 cells assessed as decrease of drug accumulation after 2 hrs relative to wild type cells	Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. — Drug Metab Dispos

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B5ZZ	C2BBe1 MRP5 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.